Quality of life in patients with peritoneal surface malignancies after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
BACKGROUND
An increasing number of patients are presenting with peritoneal carcinomatosis and more centers are performing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). While morbidity and mortality are shown to be acceptable, quality of life after surgery should be assessed.


METHODS
63 patients who had CRS and HIPEC from 2001 to 2012 and who were still alive and on follow up were included. The EORTC-QLQ-C30 was administered to the patients.


RESULTS
Median age was 53 years (14-71). 44% had ovarian primaries, 21% had appendicael primaries and 19% had colorectal primaries. Median follow-up was 1.08 years (0.06-9.8). The median time from surgery to the questionnaire was 1.3 years (0.24-10.18). There was no statistical difference in scores when comparing by age, gender, recurrence, gender, PCI score, presence of a complication and type of primary cancer. Scores were highest less than 6 months after surgery, dropped subsequently but rose again after 2 years. Our patients had better scores compared to a control group of outpatient cancer patients at our institution as well as the reference EORTC group.


CONCLUSIONS
In keeping with previous quality of life studies done for CRS and HIPEC patients, we have shown that our patients can achieve a good quality of life after CRS and HIPEC even with recurrent disease.
Department of Surgical Oncology, National Cancer Centre Singapore, Singapore.
C S
CS
Chia
Department of General Surgery, Singapore General Hospital, Singapore.
W J
WJ
Tan
Department of Surgical Oncology, National Cancer Centre Singapore, Singapore.
J F Sze
JF
Wong
Department of General Surgery, Singapore General Hospital, Singapore.
G H Ching
GH
Tan
Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, Singapore.
C
C
Lim
Department of Surgical Oncology, National Cancer Centre Singapore, Singapore.
W
W
Wang
Department of General Surgery, Singapore General Hospital, Singapore.
E I-L
EI
Sin
Department of Medical Oncology, National Cancer Centre Singapore, Singapore.
C K
CK
Tham
Department of Surgical Oncology, National Cancer Centre Singapore, Singapore.
K C
KC
Soo
Department of Surgical Oncology, National Cancer Centre Singapore, Singapore. Electronic address: Melissa.Teo.C.C@nccs.com.sg.
M C C
MC
Teo
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001063:Appendiceal Neoplasms / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods; D002681:China / Q000208:ethnology; D015179:Colorectal Neoplasms / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006304:Health Status; D006801:Humans; D006979:Hyperthermia, Induced; D007194:India / Q000208:ethnology; D008297:Male; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000473:pathology; D010529:Peritoneal Cavity; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary* / Q000601:surgery / Q000628:therapy*; D011788:Quality of Life; D012380:Role; D012846:Singapore; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Peritoneal disease; Peritonectomy; Quality of life